The global progressive pulmonary fibrosis (PPF) treatment market is witnessing robust expansion. Valued at USD 0.6 billion in 2024, it is projected to grow to USD 0.69 billion in 2025 and reach around USD 2.45 billion by 2034. This growth represents a CAGR of 15.21% between 2025 and 2034, fueled by advancements in diagnostic technologies, increasing awareness of fibrotic interstitial lung diseases, and a rising aging population.

Market Highlights

• 2024 Market Size: USD 0.6 Billion

• 2034 Forecast: USD 2.45 Billion

• CAGR (2025–2034): 15.21%

• North America’s Share (2024): 44% (Market leader)

• Asia Pacific: Fastest growing region with a strong R&D push

• Top Drug Class: Antifibrotic agents (58% market share in 2024)

• Emerging Segment: Pipeline biologics & anti-inflammatory agents

This article highlights the key companies shaping the PPF treatment landscape, their innovations, and their market impact.

---

🌟 Top Companies in the Progressive Pulmonary Fibrosis (PPF) Treatment Market

1. Boehringer Ingelheim

• About: A global pharmaceutical leader with a strong respiratory portfolio.

• Key Products: Ofev (nintedanib), a leading antifibrotic therapy for PPF and IPF.

• Market Cap: Estimated at USD 60 billion.

2. Roche Holding AG

• About: Swiss multinational known for biotechnology innovation and diagnostics.

• Key Products: Esbriet (pirfenidone) and diagnostic tools supporting early PPF detection.

• Market Cap: Around USD 240 billion.

3. Galapagos NV

• About: Belgium-based biotech focusing on inflammatory and fibrotic diseases.

• Key Products: Development-stage therapies targeting fibrosis pathways.

• Market Cap: Approx. USD 4 billion.

4. FibroGen Inc.

• About: U.S. biopharma company pioneering in fibrosis and anemia solutions.

• Key Products: Pamrevlumab, an investigational drug for PPF.

• Market Cap: Roughly USD 0.6 billion.

5. Bristol Myers Squibb

• About: A global leader in innovative therapies across multiple disease areas.

• Key Products: Biologics and pipeline therapies aimed at fibrotic conditions.

• Market Cap: Approximately USD 100 billion.

6. Bellerophon Therapeutics

• About: Specializes in innovative therapies for cardiopulmonary diseases.

• Key Products: INOpulse for pulmonary hypertension and PPF applications.

• Market Cap: Estimated at USD 50 million.

7. United Therapeutics Corporation

• About: Focuses on unmet needs in rare cardiovascular and pulmonary diseases.

• Key Products: Treprostinil-based therapies, potential PPF applications in R&D.

• Market Cap: Around USD 11 billion.

8. Vicore Pharma

• About: Swedish biotech advancing treatments for rare lung diseases.

• Key Products: C21 (angiotensin II type 2 receptor agonist) for PPF.

• Market Cap: Approximately USD 300 million.

9. Pliant Therapeutics

• About: U.S. biotech developing small-molecule therapies for fibrosis.

• Key Products: PLN-74809 in clinical trials for PPF.

• Market Cap: About USD 800 million.

10. Liminal BioSciences

• About: Specializes in novel small-molecule therapies for fibrosis.

• Key Products: Investigational assets targeting G-protein coupled receptors.

• Market Cap: Near USD 100 million.

11. Galecto Inc.

• About: Focuses on galectin inhibitors for fibrotic diseases.

• Key Products: GB0139 (inhaled galectin-3 inhibitor) in clinical development for PPF.

• Market Cap: Approximately USD 50 million.

12. Verona Pharma

• About: A respiratory disease specialist with promising pipeline assets.

• Key Products: Ensifentrine for chronic respiratory conditions, exploring PPF applications.

• Market Cap: Around USD 500 million.

13. Gilead Sciences

• About: U.S. biopharma giant with a diverse therapeutic portfolio.

• Key Products: Investigating antifibrotic agents for pulmonary indications.

• Market Cap: Roughly USD 80 billion.

14. Kadmon (Sanofi)

• About: Acquired by Sanofi, this unit focuses on rare and fibrotic diseases.

• Key Products: KD025 (belumosudil) under evaluation for fibrotic lung disorders.

• Market Cap (Sanofi): Approx. USD 140 billion.

15. Algernon Pharmaceuticals

• About: Canadian biotech exploring repurposed drugs for new indications.

• Key Products: Ifenprodil (NP-120) in clinical trials for pulmonary fibrosis.

• Market Cap: Estimated at USD 20 million.

16. Zydus Lifesciences

• About: Indian pharma major with growing global presence.

• Key Products: Developing generic antifibrotic therapies and novel agents.

• Market Cap: Approximately USD 9 billion.

Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com

---

🔥 FAQs About the Progressive Pulmonary Fibrosis Treatment Market

1. What is the expected CAGR of the PPF treatment market?

The market is projected to grow at a CAGR of 15.21% from 2025 to 2034.

2. Which region dominates the PPF treatment market?

North America dominates with a 44% market share in 2024, thanks to strong healthcare innovation.

3. Which drug class leads in the PPF treatment market?

Antifibrotic agents hold the largest share (58%) in 2024.

4. Who are the key players in the PPF treatment market?

Top companies include Boehringer Ingelheim, Roche, Galapagos NV, FibroGen, and Bristol Myers Squibb.

5. Why is the Asia Pacific region growing rapidly in this market?

Asia Pacific’s growth is driven by a robust healthcare infrastructure and increasing R&D investments.

Source : https://www.towardshealthcare.com/insights/progressive-pulmonary-fibrosis-ppf-treatment-market-sizing

Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5885